time to first ≥50% reduction in MFSAF TSS
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jean-Jacques Kiladjian, Uma Borate, Elisabetta Abruzzese, Valerio De Stefano, Tiejun Gong, Massimo Breccia, Francesca Palandri, Fabrizio Pane, Andrea Patriarca, Hakon Reikvam, Lindsay Rein, Abdulraheem Yacoub, Feng Zhou, Michael Stouffs, Albert Assad, Alessandro Maria Vannucchi
Oncologist 31(7) oyag201
BACKGROUND: Ruxolitinib (JAK1/JAK2 inhibitor) is indicated for adults with intermediate or high-risk myelofibrosis; however, a subset of patients may exhibit a suboptimal response due to persistent PI3K/AKT activation. The phase 3, randomized, double-blind, placebo-controlled LIMBER-304 study (NCT04551053) investigated the efficacy and safety of add-on parsaclisib (highly selective PI3Kδ inhibitor) in patients with myelofibrosis and suboptimal or declining response to stable ruxolitinib monotherapy. PATIENTS AND METHODS: Adults with primary or secondary myelofibrosis who received ruxolitinib with palpable spleen and Myelofibrosis Symptom Assessment Form (MFSAF) total symptom score (TSS) ≥10 were eligible. Primary end point was proportion of patients achieving ≥25% spleen volume reduction (SVR; baseline to week 24); key secondary end point was proportion of patients with ≥50% MFSAF-TSS reduction (baseline to week 24). RESULTS: In total, 90 patients received parsaclisib/ruxolitinib; 87 received placebo/ruxolitinib. At week 24, 16.7% of patients receiving parsaclisib/ruxolitinib achieved ≥25% SVR vs 9.7% for placebo/ruxolitinib; this difference was not statistically significant. By week 24, ≥50% reduction in MFSAF-TSS was observed in 17.1% of patients receiving parsaclisib/ruxolitinib vs 14.1% for placebo/ruxolitinib. Higher rates of infections (including cytomegalovirus) and gastrointestinal disorders were observed with parsaclisib/ruxolitinib. Grade ≥3 treatment-emergent adverse events occurred in 60.0% of patients receiving parsaclisib/ruxolitinib vs 42.5% with placebo/ruxolitinib. The study was terminated early based on efficacy findings. CONCLUSIONS: Study results suggested adding parsaclisib to stable-dose ruxolitinib was unlikely to offer clinically meaningful benefits. Further research is needed on the potential of JAK and PI3K inhibitor-based combination therapy for patients with myelofibrosis.
1 个 Figure · 1 个 KM 面板
Figure 3. Change in MFSAF TSSs from baseline and likelihood of achieving a ≥50% reduction from baseline in MFSAF TSS in patients with myelofibrosis. (A) Percentage change in MFSAF TSS from baseline to week 24 (individual patient data; n = 117). Dotted line represents a 50% decrease in MFSAF TSS from baseline. (B) Median percentage change in MFSAF TSS from baseline. (C) Kaplan-Meier estimates of time to first ≥50% reduction in MFSAF TSS from baseline. Hashtags indicate patients with >100% percent change in MFSAF TSS from baseline. Tick marks indicate censored data. MFSAF, Myelofibrosis Symptom Assessment Form; TSS, total symptom score.
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。